Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study

Fig. 5

ROCs for CN+ participants. A The discriminative power of individual plasma Aβ markers and the combined panel in identifying CN+ from CN−; B The discriminative power of each of the gut taxa and the combined panel in identifying CN+ from CN−; C The predicted values of the combined panels in identifying CN+ from CN−. Aβ, amyloid-β; CN−, amyloid-β-negative cognitively normal participants; CN+, amyloid-β-positive cognitively normal participants; panel 1, the combined plasma Aβ40, Aβ42, and Aβ42/ Aβ40; panel 2, the combined taxa 1, taxa 2, and taxa 3; panel 3, the combined clinical cognitive tests (including MoCA-B, AVLT-long delayed recall, AVLT-R, STT-A, STT-B, AFT, BNT); panel 4, the combined plasma Aβ markers, gut taxa, and cognitive tests

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193